Baiwangda Health Tech Industrial Park Empowers Biopharma Enterprises and Drives Industrial Upgrading in Longgang, Shenzhen

The Rapid Rise of China’s Biopharmaceutical Parks Is Becoming a New Engine Driving Innovation and Economic Growth in the Domestic Pharmaceutical Industry.

In recent years, driven by the dual forces of national policy support and market demand, biomedical industrial parks in China have sprung up like mushrooms after rain. They have not only experienced rapid growth in number but also demonstrated new potential in operational models, service systems, and innovation capabilities, becoming a significant driving force for the rapid and high-quality development of regional biomedical industries.

These parks typically rely on policy support from local governments, technological innovation from research institutions, and capital investment from enterprises, forming an integrated industrial chain encompassing R&D, production, and sales. Currently, domestic biomedical industrial parks are moving toward specialization, clustering, and internationalization, aiming to secure a place in the global biomedical industry.

As a vital component of the Guangdong-Hong Kong-Macao Greater Bay Area, Longgang District in Shenzhen has achieved remarkable progress in the healthcare industry in recent years. Leveraging its strategic location, robust infrastructure, and open innovation ecosystem, Longgang is actively cultivating a biomedical industrial ecosystem, attracting numerous biomedical enterprises to establish operations in the district. The Longgang District Government has also provided strong support and guarantees for the development of the biomedical industry by implementing a series of preferential policies.

Baiwangda Health Technology Industrial Park is a specialized biomedical industrial park built to high standards in Longgang District in recent years. With its state-of-the-art facilities and professional services, the park has injected new vitality into the prosperity of Longgang District’s biomedical industry and is poised to establish the region as a hub for biomedical innovation.

The relationship between industrial parks and enterprises is mutually reinforcing. Supporting park services, carrier platforms, policy advantages, and other factors can significantly benefit the growth of biopharmaceutical companies. So, what are the advantages of Baiwangda Health Technology Industrial Park, and how exactly does it strategically navigate this landscape?

The Baiwangda Health Technology Industrial Park is a key project constructed and operated by Shenzhen Zhifeideng Technology Co., Ltd. The company is a subsidiary of the Weiyue Group, which has been assisting factory owners in constructing industrial facilities since the 1990s and possesses over 20 years of experience in developing industrial parks and commercial office buildings.

In 2014, Yuewei Group entered the real estate market by acquiring and operating international Grade A+ office buildings. Currently, it holds, operates, and manages two Grade A+ office buildings in the core area of Nanshan Science and Technology Park, as well as factory and industrial park projects exceeding one million square meters in Longgang’s Bantian, Henggang, Zhangbei, and Aobei areas.

The establishment of the Baiwangda Health Technology Industrial Park is based on Longgang District’s active integration into Shenzhen’s “20+8” industrial clusters and the implementation of the regional development strategy of “One Core, Two Nuclei, and Multiple Support Points.” Construction of the Baiwangda Health Technology Industrial Park project commenced in June 2020, with a total investment of approximately RMB 1.3 billion. The project covers an area of 57,800 square meters, with a total gross floor area of approximately 230,000 square meters, including approximately 150,000 square meters dedicated to high-standard factory buildings and R&D offices. The project has now been fully completed and delivered for use, becoming the first biomedical professional park in Longgang District to be delivered.

According to reports, the industrial park specializes in biopharmaceuticals, medical devices, and high-tech industries, aiming to establish itself as a pioneering zone for biopharmaceuticals in Longgang District, Shenzhen.

Leveraging the project’s regional and product advantages, the industrial park is strategically focusing on the entire biopharmaceutical value chain—“R&D + Clinical Trials + Manufacturing + Application.” It is actively developing public service platforms and targeting niche sectors such as cell and gene therapy, innovative drug R&D, high-end medical aesthetics, and advanced medical device manufacturing, with the aim of accelerating the formation of a landmark industrial cluster.

With numerous biopharmaceutical industrial parks in China, professionalism and differentiation are crucial to standing out.

For the Baiwangda Health Technology Industrial Park, although it is currently in its early stages, it has gathered multiple advantages in terms of policy, location, platform, and services. These strengths will serve as core elements driving the advancement of the biopharmaceutical industry.

First, the location offers convenient transportation and strategic advantages. The Baiwangda Health Technology Industrial Park is situated in the launch area of the Apollo Future Industry City, Yuanshan Subdistrict, Longgang District, Shenzhen—a key node in Shenzhen Longgang’s “One Core, Two Nuclei, Multiple Support Points” strategic layout. The Apollo Future Industry City enjoys rapid connectivity with the city’s core areas and key cities in the Greater Bay Area, with direct rail transit access to the city center. Notably, the Apollo South Station on Metro Line 16, scheduled to open in the first half of 2025, will provide seamless connectivity to the park.

Secondly, in terms of policy, in December 2023, the Longgang District Science and Technology Innovation Bureau issued the "Notice on Several Measures of Shenzhen Longgang District to Promote High-Quality Development of the Biopharmaceutical Industry," deeply implementing the innovation-driven development strategy, accelerating the aggregation of scientific and technological innovation resources, and increasing support for the development of the biopharmaceutical industry in Longgang District. Relying on special policies for the biopharmaceutical industry, strong policy support is provided in areas such as research and development funding support, industrial ecosystem construction, industrial cluster development, and site rental subsidies, to promote high-quality development of the biopharmaceutical industry and facilitate the clustered development of leading industries.

Meanwhile, the industrial park also boasts significant advantages in specialized services. For instance, the centralized construction of professional supporting facilities, such as environmental protection treatment systems, addresses common production challenges faced by enterprises, thereby reducing their operational and production costs. Additionally, the park’s specialized investment promotion and operations team provides resident enterprises with professional industrial, policy, and financial services.

From the perspective of resident enterprises, these advantages will provide comprehensive empowerment, encompassing infrastructure support, professional services, innovation and collaboration opportunities, as well as policy and financial backing. This will help enhance operational efficiency, management standards, and competitiveness, thereby driving sustainable corporate development.

For resident enterprises, in addition to policies, talent, and resource needs, innovative industrial ecosystem services are also an indispensable component supporting the park’s innovative development.

From this perspective, the industrial park is further strengthening the introduction of public service platforms and specialized incubators, achieving integrated investment promotion across the industrial chain through these professional platforms. Meanwhile, it is establishing a “capital empowerment platform” to explore investment promotion models such as “fund + base” and “investment + industry,” thereby attracting more high-quality projects and enterprises to settle in the park. Focusing on the industrial chain, the park is cultivating innovation chains, service chains, talent chains, and capital chains, so as to provide full-lifecycle services for the biopharmaceutical industry, from innovative R&D to product commercialization.

Supported by multiple core advantages, the development pace of Baiwangda Health Technology Industrial Park is visibly rapid. Currently, the park has attracted renowned enterprises such as NAURA Technology Group, Hunan Sun Simiao Pharmaceutical, The Chinese University of Hong Kong’s New Medical Innovation and Development Research Institute, Jiewo Medical, Jianxing Pharmaceutical, and Hengyijing Technology. Among them, NAURA Technology Group is a leading enterprise in China’s semiconductor industry.

Looking ahead, the park will achieve rapid project absorption in the short term, continuously attract leading enterprises and high-end industries in life and health, and build a preliminary high-quality biomedical industrial cluster. By establishing a technology transfer system, public service platforms, an investment and financing ecosystem, a vibrant industrial atmosphere, and comprehensive business and living amenities, the park will support the innovative development of its enterprises.

In the future, Baiwangda Health Technology Industrial Park will strive to become one of the few specialized biomedical hubs in the Greater Bay Area.

For more details, please contact: 897038391@qq.com